<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008536</url>
  </required_header>
  <id_info>
    <org_study_id>BCMA NK for MM</org_study_id>
    <nct_id>NCT05008536</nct_id>
  </id_info>
  <brief_title>Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Phase I Study to Evaluate the Safety and Effectiveness of Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to infuse BCMA CAR-NK cells（Umbilical &amp; Cord Blood (CB) Derived&#xD;
      CAR-Engineered NK Cells） to the patients with relapsed and refractory multiple myeloma (MM),&#xD;
      to assess the safety and feasibility of this strategy. The CAR enables the NK cells to&#xD;
      recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of&#xD;
      the malignant plasma cells in MM patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Anti-BCMA CAR-NK Cells</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Remission Rate (ORR)</measure>
    <time_frame>2 monthes after infusion</time_frame>
    <description>Response assessment per International Myeloma Working Group (IMWG) criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicity (DLTs)</measure>
    <time_frame>within 2 monthes after infusion</time_frame>
    <description>To characterize the safety, tolerability of Anti-BCMA CAR-NK Cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Response assessment per International Myeloma Working Group (IMWG) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Response assessment per International Myeloma Working Group (IMWG) criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Multiple Myeloma, Refractory</condition>
  <arm_group>
    <arm_group_label>Anti-BCMA CAR-NK Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After preconditioning with chemotherapy, the Anti-BCMA CAR-NK Cells will be evaluated</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-BCMA CAR-NK Cells</intervention_name>
    <description>1-3×10^6 /KG, 3-6×10^6 /KG, 0.6-1.2×10^7/KG Treatment follows a lymphodepletion</description>
    <arm_group_label>Anti-BCMA CAR-NK Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>recommendation: 30mg/m2 (D-5~D-3),determined by tumor burden at baseline.</description>
    <arm_group_label>Anti-BCMA CAR-NK Cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytoxan</intervention_name>
    <description>recommendation: 300-500mg/m2 (D-5~D-3),determined by tumor burden at baseline.</description>
    <arm_group_label>Anti-BCMA CAR-NK Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent;&#xD;
&#xD;
          2. According to the international standard for multiple myeloma，have information on&#xD;
             medical examination proving the diagnosis of multiple myeloma.&#xD;
&#xD;
          3. Received at least 2 prior lines of treatment, including proteasome inhibitor and&#xD;
             immunomodulator, no efficacy more than PD; disease progression or relapsed after&#xD;
             disease remission and refractory or no remission after treated in the last time.&#xD;
&#xD;
          4. Measurable disease at screening as defined by any of the following: Serum monoclonal&#xD;
             paraprotein (M-protein) level ≥1.0 g/dL or urine M-protein level veing as defined ；or&#xD;
             light chain MM without measurable disease in the serum or the urine；serum&#xD;
             immunoglobulin free light chain isease dL and abnormal serum immunoglobulin&#xD;
             kappa/lambda free light chain ratio ；&#xD;
&#xD;
          5. ECOG Scores: 0~2（See Annex 3），the estimated survival time was more than 3 months;&#xD;
&#xD;
          6. During the screening period, the clinical laboratory values met the following&#xD;
             criteria： Hemoglobins70g/L (did not receive red blood cell transfusion ≤7 days prior&#xD;
             to laboratory tests，recombinant human erythropoietin is allowed); Platelet count&#xD;
             &gt;50×10^9/L (did not receive blood transfusion ≤7 days prior to laboratory tests);&#xD;
             Neutrophil absolute count oietin is (did not receive supportive treatment lowed);&#xD;
             Platelet count &gt;50×10^9/L，allowed to use over growth factor support); ALT and AST&#xD;
             ≤3×ULN；Total bilirubin ≤2.0× UNL；Creatinine clearance×40mL/min；corrected serum calcium&#xD;
             L/minctordL (3.1 mmol/L), or free calcium ion or freedL(L( ommol/L); Prothrombin time&#xD;
             and activated partial thromboplastin time ≤1.5×ULN.&#xD;
&#xD;
          7. The urine pregnancy test of female subjects of childbearing age should be negative and&#xD;
             not in lactation;&#xD;
&#xD;
          8. Females of childbearing potential and males must use efficient contraception（form&#xD;
             signing the ICF to the end of the trial）&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have received CAR-NK therapy；&#xD;
&#xD;
          2. Have a history of allergy to any component of cell products;&#xD;
&#xD;
          3. Previous history of other malignancy;&#xD;
&#xD;
          4. Any unstable cardiovascular disease happened the informed consent form by themselves&#xD;
             or their legal guardian;boratory tests); be infused using the &quot;3 + 3&quot; dos grade),&#xD;
             severe arrhythmia that require drug interference, cardiac angioplasty/coronary stent&#xD;
             implantation/cardiac bypass surgery ≤6 months prior to enrollment;&#xD;
&#xD;
          5. Have received allogeneic hematopoietic stem cell transplantation in 3 months for the&#xD;
             treatment of multiple myeloma;&#xD;
&#xD;
          6. who has suffered from brain injury, consciousness disorder, epilepsy, more serious&#xD;
             cerebral ischemia or cerebral hemorrhage disease;&#xD;
&#xD;
          7. There were live vaccinations within 4 weeks before admission;&#xD;
&#xD;
          8. Active hepatitis (positive for HBVDNA or HCVRNA), syphilis and other acquired and&#xD;
             congenital immunodeficiency diseases, including but not limited to those with HIV&#xD;
             infection;&#xD;
&#xD;
          9. Oxygen is needed to maintain adequate oxygen saturation;&#xD;
&#xD;
         10. Contraindications for fludarabine or cyclophosphamide treatment.&#xD;
&#xD;
         11. There was uncontrolled active infection;Patients with autoimmune diseases,&#xD;
             immunodeficiency or other diseases requiring immunosuppressive （excluding&#xD;
             glucocorticoid）therapy;&#xD;
&#xD;
         12. Pregnant or breasting-feeding women;&#xD;
&#xD;
         13. Subjects had a history of alcohol, drug or mental illness;&#xD;
&#xD;
         14. Any other condition that researcher think it is inappropriate for the subject to&#xD;
             anticipate the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xi zhang, PhD/MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Hematology, Xinqiao Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>xi zhang, PhD/MD</last_name>
    <phone>13808310064</phone>
    <phone_ext>+86</phone_ext>
    <email>zhangxxi@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ruihao huang, MD</last_name>
    <phone>18984398751</phone>
    <phone_ext>+86</phone_ext>
    <email>1169731117@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology, Xinqiao Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 14, 2021</study_first_submitted>
  <study_first_submitted_qc>August 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 14, 2021</last_update_submitted>
  <last_update_submitted_qc>August 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Xi Zhang, MD</investigator_full_name>
    <investigator_title>Chef of Hematology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

